Table 2.

Patient characteristics associated with the receipt of aggressive thoracic therapy.

Characteristic	ATT	Non-ATT	p
N	38	28
Age, median	55 years	60.5 years	0.027
Sex			1.000
Male	14 (37%)	10 (36%)
Female	24 (63%)	18 (64%)
KPS*			0.200
80-100	27 (84%)	16 (67%)
70	5 (16%)	8 (33%)
Histology			0.104
Adenocarcinoma	25 (66%)	13 (46%)
Squamous cell	6 (16%)	3 (11%)
NSCLC NOS	7 (18%)	12 (43%)
Thoracic stage			0.390
I	7 (18%)	2 (7%)
II	6 (16%)	4 (14%)
III	25 (66%)	12 (79%)
Number of brain metastases			1.000
1	19 (50%)	14 (50%)
2-4	19 (50%)	14 (50%)
Size of largest brain metastasis*			0.495
≤ 3 cm	30 (81%)	25 (89%)
> 3 cm	7 (19%)	3 (11%)
Initial CNS therapy			0.480
WBRT + SRS and/or Surgery	21 (55%)	14 (50%)
WBRT only or Surgery +/− SRS	15 (39%)	14 (50%)
None	2 (5%)	0 (0%)

^*Totals do not add up due to missing data.

NOS: not otherwise specified; KPS: Karnofsky performance status; NSCLC: non-small cell lung cancer; CNS: central nervous system; WBRT: whole brain radiotherapy; SRS: stereotactic radiosurgery; ATT: aggressive thoracic therapy